Suppr超能文献

临床试验统计学与临床前方法的区别,以及为什么稳健的方法很重要。

What differentiates clinical trial statistics from preclinical methods and why robust approaches matter.

出版信息

Nat Commun. 2024 Aug 15;15(1):7035. doi: 10.1038/s41467-024-51486-4.

Abstract

Clinical trial statistics underlie the central decision-making process for whether a therapeutic approach can enter the clinic, but the nuances of this field may not be widely understood. Furthermore, how the statistics used in clinical trials differ from preclinical approaches and why they differ is not always clear. Here, three experts discuss the intricacies of clinical trial statistical planning and analysis as well as common issues that arise and emerging trends. The experts are Dr Tao Chen (Senior lecturer in Biostatistics at the Liverpool School of Tropical medicine), Professor Li Chao (Professor in Biostatistics at Xi’an Jiaotong University) and Professor Yang Wang (Professor in Biostatistics at the Chinese Academy of Medical Sciences and Peking Union Medical College). They have a diverse range of backgrounds across biostatistics and have been involved in numerous clinical trials of varying types.

摘要

临床试验统计数据是决定治疗方法是否能够进入临床应用的核心决策过程的基础,但该领域的细微差别可能并不广为人知。此外,临床试验中使用的统计方法与临床前方法有何不同,以及为什么会有所不同,也并不总是很清楚。在这里,三位专家讨论了临床试验统计规划和分析的复杂性,以及常见问题和新兴趋势。这三位专家是陶晨博士(利物浦热带医学院生物统计学高级讲师)、李超教授(西安交通大学生物统计学教授)和王扬教授(中国医学科学院北京协和医学院生物统计学教授)。他们在生物统计学方面拥有不同的背景,并且参与了许多不同类型的临床试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9451/11327279/5267f4bdd059/41467_2024_51486_Figa_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验